onvansertib
Small moleculeexperimental
Clinical trial activity
12 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Nov 17, 2017 (NCT03303339)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Genes, ras · Phase 2
- Inflammatory Breast Neoplasms · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Mutation · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Serine/threonine-protein kinase PLK1INHIBITOR
PLK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1- Mol. weight
- 532.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1738758 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06736717 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | Cardiff Oncology, University of Kansas |
| NCT06398587 | Phase 2 | Aug 1, 2024 | OHSU Knight Cancer Institute, Oregon Health and Science University |
| NCT06106308 | Phase 2 | Nov 16, 2023 | Cardiff Oncology, Pfizer |
| NCT05593328 | Phase 2 | Dec 31, 2022 | Cardiff Oncology |
| NCT05549661 | Phase 1 | Nov 21, 2022 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT05383196 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Cardiff Oncology, Harvard University |
| NCT05450965 | Phase 2 | Jul 19, 2022 | Cardiff Oncology, National Institutes of Health (NIH), University of Pittsburgh |
| NCT04752696 | Phase 2 | May 3, 2021 | Cardiff Oncology |
| NCT03829410 | Phase 1/Phase 2 (Phase 2) | May 6, 2019 | Cardiff Oncology |
| NCT03414034 | Phase 2 | Jun 18, 2018 | Cardiff Oncology |
| NCT03303339 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2017 | Cardiff Oncology |
| NCT04446793 | N/A | — | Cardiff Oncology |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cardiff Oncology | For profit | 10 | 7 | 2 | 2017 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
| OHSU Knight Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Pfizer | For profit | 1 | 0 | 1 | 2023 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2022 |
10 organizations
Page 1 / 1